I did exactly this. Moved my buy up from 2.1 to 2.5, will see how we go. If management keep announcing contracts and developments, I suspect even my higher buy is unlikely to get filled
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling